autoimmune diseases

IN8bio showcases gamma-delta T cell advances and glioblastoma survival data at May 2026 R&D Day and major medical conferences.

argenx will report Q1 2026 financial results on May 7, 2026, offering investors insight into the immunology company's clinical progress and commercial trajectory.

Clinical-stage biotech Jade Biosciences appoints Dr. Edward Conner as CMO, grants 500,000 stock options valued at $12.7M as inducement under Nasdaq rules.

Bispecific antibody market projected to reach $60 billion by 2031 from $16 billion in 2025, with 550+ clinical trials and 18 approved drugs driving sector transformation.

Clinical-stage biotech Neutrolis appoints Caren Deardorf as Chief Business & Strategy Officer, bringing 30 years of pharma commercialization expertise as company advances NTR-1011 candidate.

Artiva Biotherapeutics to present AlloNK cell therapy pipeline at Needham Healthcare Conference on April 15, 2026, advancing three ongoing autoimmune disease trials.

$CBPO secures $7.5M milestone from Boehringer Ingelheim partnership, with $337.5M upside potential as lead compound advances to optimization.

IN8bio issued 11,800 stock options to two new employees on April 1, 2026, as hiring incentives under Nasdaq listing regulations.

Vor Bio awarded stock options and RSUs to nine newly hired employees as employment inducements, with options exercisable at $17.39 per share over a 10-year term.

Galapagos and Gilead form binding collaboration on gamgertamig, an autoimmune T cell engager, with Galapagos receiving 50% of Gilead's $1.675B Ouro Medicines acquisition.

InnoCare Pharma achieved 644 million yuan profit in 2025, two years ahead of schedule, driven by product sales and licensing partnerships. Hong Kong-listed shares trade at modest 14x P/S ratio.

Zenas BioPharma prices $300M offering combining $200M convertible notes and 5M common shares to fund obexelimab launch and pipeline advancement.

Galapagos and Gilead plan to jointly develop an Ouro T cell engager for autoimmune diseases, splitting acquisition costs while Galapagos leads development and Gilead commercializes, freeing $500M in Galapagos cash.

Galapagos and Gilead are in advanced partnership talks for a first-in-class T-cell engager for autoimmune diseases, with 50% cost-sharing and €500 million capital freed for Galapagos.

Anaveon appoints veteran biotech executive Thaminda Ramanayake as CEO to guide lead candidate ANV200 through clinical development for autoimmune and inflammatory diseases.

ENAVATE deepens Zenas BioPharma stake to $142.3M. Key catalyst: obexelimab Phase 2 lupus data and Q2 2026 FDA submission.

Dianthus Therapeutics prices $625M upsized offering at $81/share to fund drug development and commercial readiness. Closing expected March 12, 2026.

Jade Biosciences reports $127.4M full-year loss, maintains $336.2M cash runway through mid-2028 with pipeline data catalysts starting Q2 2026.

Rallybio soars as merger with $505M-backed Candid Therapeutics creates combined biotech with $700M cash runway through 2030.

Danish biotech $EVAX will announce full-year 2025 financial results and business update March 5, detailing AI-Immunology platform development across oncology, infectious disease, and autoimmune applications.